Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients

NCT06701734 | Not Yet Recruiting

• 1 other identifier: Chronic_pain_DPA714 PET
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

Chronic pain is a major public health issue, which seriously affects patients' quality of life. Neuroinflammation is an important mechanism resulting in chronic pain. Translocator protein (TSPO) has served as a marker of microglial activation and neuroinflammation. 18F-DPA714, a tracer targeted TSPO, can be used to evaluate the microglial activation and neuroinflammation in vivo by PET imaging.Recent and increasing studies have found changes in TSPO and its ligands in various chronic pain models. Reversing their expressions has been shown to alleviate chronic pain in these models, illustrating the effects of TSPO and its ligands.The investigators aim to explore the clinical feasibility used 18F-DPA714 PET imaging to monitor microglial cells activation of center nervous system in chronic pain patients. This study might reveal significant neuroinflammatory process in the center nervous system of the chronic pain patients. The results of this study might provide a new biomarker of disease pathological progression and indicates that TSPO-based therapy may become an alternative strategy for treating chronic pain.

Conditions

Chroinc Pain; PET; Microglial Activation

Outcome Measures

Primary Outcomes (1)

• Standardized Uptake Value

  Measures of specific binding of 18F-DPA-714 measures of specific binding of the tracer

  2 years

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with chronic pain

You may qualify if:

• chronic pain patients
• Written informed consent was provided by the patients and their family

You may not qualify if:

• history of head trauma ， epilepsy， claustrophobia, rheumatic or autoimmune diseases, psychiatric disorders, severe somatic diseases (neurological,cardiovascular, etc.),previous heart or brain surgery, substance abuse, inability to refrain from hypnotics, magnetic implants, pregnancy, lactation

Sponsors & Collaborators

• Weibing Miao, PhD: lead

Biospecimen

Retention: SAMPLES WITH DNA

blood

Central Study Contacts

Qianqian Xue

CONTACT

+8618558799064; xueqian124@163.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: November 16, 2024
• First Posted: November 22, 2024
• Study Start: December 1, 2024
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: November 22, 2024

Record last verified: 2024-11